Ablace Implantabilní kardioverter-defi brilátor Komorové arytmie Mexiletin Srdeční selhání SOUHRN Popisujeme případ 78letého muže, který byl převezen na naše oddělení pro četné epizody maligních komorových arytmií neodpovídajících na předchozí antiarytmickou léčbu (optimalizace nastavení zařízení, podávání amiodaronu, infuze lidokainu a optimální farmakoterapie). Pacient byl navíc v terminálním stadiu srdečního selhání ischemické etiologie a měl implantován CRT-D. Po vyloučení sekundárních příčin elektrické bouře a vzhledem k neúčinnosti farmakoterapie jsme přistoupili k radiofrekvenční ablaci. První den po výkonu došlo k recidivě život ohrožujících komorových tachykardií/fi brilací komor. Jako poslední možnost jsme upravili léčbu a začali pacientovi podávat mexiletin s následným úplným vymizením komplexních komorových arytmií. Při neúčinné léčbě amiodaronem může mexiletin představovat účinné alternativní antiarytmikum.
Introduction
Electrical storm (ES) is a state of cardiac electrical instability. Typically, it affects older men with coronary artery disease [1] . Amiodarone plus -blocker is the most effective therapy to prevent ventricular tachycardia (VT) or ventricular fi brillation (VF) in patients with implanted cardioverter-defi brillator (ICD) [2] . However, while inefficient, alternative medications and methods might to be considered. We present a case of 78-year-old male patient in whom we managed to successfully use one of such alternative medications -mexiletine.
Case report
We present a case of 78-year-old male transferred to Department of Cardiology due to multiple episodes of malignant ventricular arrhythmias refractory to previous antiarrhythmic treatments including device settings optimization, antiarrhythmic drug therapy (amiodarone, lidocaine) and optimal pharmacotherapy. The patient had history of biventricular, end-stage heart failure (HF) due to ischemic dilated cardiomyopathy, enlarged left ventricle up to 78 mm in diastole and systolic dysfunction with ejection fraction (LVEF) 15%, apex aneurysm with thrombus, permanent atrial fi brillation, third-degree atrioventricular block, hypertension, diabetes mellitus type 2 and chronic kidney disease. He underwent inferior wall myocardial infarction 24 years ago that was treated conservatively and primary PCI with stent implantation in the left anterior descending artery complicated by sudden cardiac arrest 8 years ago. Eight years earlier patient underwent ICD implantation (as the secondary prevention of sudden cardiac death [SCD]), which was followed by upgrade to cardiac resynchronization therapy-defi brillator (CRT-D) 4 years later.
Before transfer to our Department the patient was hospitalized due to infectious exacerbation of congestive HF (CHF). Prior to ES initiation for couple of weeks patient suffered from respiratory tract infection, refractory to different courses of antibiotics. Sustaining elevation of infectious parameters clinically resulted in CHF exacerbation, what led to ES. During previous hospitalizations, multiple unsuccessful attempts to modify CRT-D settings were made, i.e. higher-rate detection threshold of VT, VT overriding, different antitachycardia pacing (ATP) algorithms or when unsuccessful or hemodynamically unstable ICD-initiated cardioversions. To achieve stabilization of the general state, the patient required continuous amiodarone administration and intravenous lidocaine infusion.
In our Department, we observed hemodynamically unstable cardiac arrhythmias -monomorphic, degenerating to polymorphic VT and VF ( Potassium and magnesium level on admission were 4.6 mmol/L and 1.1 mmol/L, respectively. Initial corrected QT interval (QTc) was 430 ms. Due to elevated infl ammation parameters, antibiotic therapy was continued. Before transfer to our Department the patient received amoxicillin with clavulanic acid (which do not prolong QTc). We switched the therapy to clarithromycin with ciprofl oxacin. Additionally, optimal pharmacotherapy for CHF exacerbation, including angiotensin II receptor blocker, -blocker, statin, spironolactone and furosemide in maximal tolerated doses, was continued.
Cardiac arrhythmias were refractory to antiarrhythmic drugs and caused further deterioration of patient's clinical status. On the 3rd day in our Department we tried to ablate VT, which originated from LV (Fig. 1B) . Before and during the procedure the patient received vancomycin, as prophylaxis. Programmed ventricular stimulation induced monomorphic VT, cycle length 430 ms with alternans. There were 2 dominating PVC morphologies and they were considered the ablation's target. After procedure programmed ventricular stimulation did not induce VT. Early post-procedure period was uneventful. On the 1st day after intervention we observed aggravation of life-threating, hemodynamically unstable, cardiac arrhythmias. Patient received additionally amiodarone p.o., continuous i.v. infusion of midazolam and xylocaine in up-titrated doses. We withdrew metoprolol and introduced carvedilol and gave fractioned s.c. doses of morphine. Additionally, we made temporary attempt to inactivate ATP. Due to Clostridium diffi cile infection the antibiotic therapy was switched one more time -to vancomycin p.o.
Four days after radio-frequency ablation due to sustaining life-threatening condition we decided to withdraw amiodarone (QTc = 420 ms) and introduced therapy with mexiletine. The initial dose was 400 mg 3-times per day and was up-titrated up to 400 mg 4-times per day. After mexiletine administration we did not observe any complex cardiac arrhythmias. We noted gradual stabilization and improvement of patient's general clinical status.
Discussion
Electrical storm is common in ICD patients, occurring in about 7% of them, which is signifi cantly more frequent than in CRT-D patients (about 0.6%) [3] . However, some other studies show the ES occurrence in patients with CRT-D of about 7% [4] . The ES risk factors include: low LVEF, device implantation in the secondary SCD prevention and age over 65 [3] [4] [5] . All of them were present in our patient. In our case ES was in a shape of recurring preserved monomorphic VTs, caused by single premature ventricular contractions (PVCs), degenerating to polymorphic VTs and VF due to antiarrhythmic stimulation. All of them required multiple interventions, from both CRT-D and external defi brillator. The fact that CRT-D may trigger monomorphic and polymorphic VT was reported in the literature [6] [7] [8] [9] [10] . Izquierdo et al. showed that in patients with ES there was no difference, in neither survival nor ES recurrence in over 2 years follow-up after an episode of ES, between ablation and conservative treatment. They also showed that poor LVEF was associated with higher recurrence of ES in patients who underwent ablation [11] . Nayak et al. showed that the best way to manage monomorphic VT in CRT-D patients suffering from ES, was to either ablate arrhythmic substrate, or to turn off LV pacing and then introduce long-term antiarrhythmic pharmacological therapy [12] . According to the latest guidelines urgent catheter ablation is indicated in patients with scar-related heart disease presenting with ES [13] . We took all of the above data under consideration and went on with ablation as our fi rst choice. Recently Murata et al. reported incidence of amiodarone--refractory ES of 30% and at the same time Gao et al. showed that in case of amiodarone ineffi cacy, introduction of mexiletine reduced number of VT or VF events in ICD patients (although mexiletine-therapy in long-term follow-up did not reduce number of shocks) [14, 15] . Although small cardiodepressant effect after mexiletine administration in patients with HF was described, data are inconclusive [16, 17] . It may be associated with impaired mexiletine clearance in patients with HF [18] . The reason why mexiletine might be effi cient may be that it blocks sodium channels. That might reduce number of PVC originating from Purkinje network [19] . Mexiletine may also infl uence proarrhythmic effects of class III agents due to downscaling of QT-prolonging effects [19] . Moreover, cardioprotective effect of mexiletine was also described. It might be due to opening of adenosine triphosphate--sensitive potassium channels, thus preventing calcium overload and leading to protection against both ischemia-and reperfusion-injury [20] .
Although ICD and CRT-D implantations are life-saving therapies, used widely as prevention of SCD, they could also trigger cardiac arrhythmias, including ES. Amiodarone -the most widely used antiarrhythmic drug -sometimes proves ineffi cient and then other medications should be considered. Mexiletine, with its described cardioprotective properties, seems to be benefi cial alternative for patients with recurrent ES refractory to other therapies, including ablation, as shown in our case. It might be also considered safe in some patients with severely impaired LVEF.
Confl ict of interest
The authors declare that they have no confl ict of interest.
Funding body
None.
Ethical statement
Authors state that the research was conducted according to ethical standards.
Informed consent
I declare that informed consent to publish the results was given by all the patients.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.crvasa.2017.06.011.
